Alligator Bioscience Past Earnings Performance
Past criteria checks 0/6
Alligator Bioscience's earnings have been declining at an average annual rate of -5.9%, while the Biotechs industry saw earnings declining at 1.4% annually. Revenues have been growing at an average rate of 30.4% per year.
Key information
-5.9%
Earnings growth rate
25.5%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | 30.4% |
Return on equity | -2,096.9% |
Net Margin | -419.5% |
Next Earnings Update | 06 May 2024 |
Recent past performance updates
Recent updates
Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?
Dec 01We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate
Dec 21Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?
Jul 30Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?
Jan 06Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation
Aug 18Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation
Apr 11Estimating The Intrinsic Value Of Alligator Bioscience AB (publ) (STO:ATORX)
Feb 17Have Insiders Been Buying Alligator Bioscience AB (publ) (STO:ATORX) Shares?
Jan 13Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?
Dec 09Revenue & Expenses BreakdownBeta
How Alligator Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 59 | -249 | 79 | 0 |
30 Sep 23 | 68 | -232 | 76 | 0 |
30 Jun 23 | 53 | -231 | 75 | 0 |
31 Mar 23 | 40 | -213 | 72 | 0 |
31 Dec 22 | 36 | -193 | 69 | 0 |
30 Sep 22 | 21 | -177 | 65 | 0 |
30 Jun 22 | 20 | -163 | 63 | 0 |
31 Mar 22 | 18 | -152 | 59 | 0 |
31 Dec 21 | 13 | -142 | 57 | 0 |
30 Sep 21 | 8 | -139 | 54 | 0 |
30 Jun 21 | 5 | -133 | 51 | 0 |
31 Mar 21 | 6 | -133 | 53 | 0 |
31 Dec 20 | 6 | -143 | 56 | 0 |
30 Sep 20 | 5 | -169 | 59 | 0 |
30 Jun 20 | 9 | -194 | 62 | 0 |
31 Mar 20 | 4 | -209 | 62 | 0 |
31 Dec 19 | 4 | -210 | 61 | 0 |
30 Sep 19 | 30 | -181 | 60 | 0 |
30 Jun 19 | 26 | -164 | 58 | 0 |
31 Mar 19 | 26 | -152 | 55 | 0 |
31 Dec 18 | 27 | -150 | 52 | 0 |
30 Sep 18 | 53 | -107 | 54 | 0 |
30 Jun 18 | 54 | -93 | 51 | 0 |
31 Mar 18 | 55 | -86 | 48 | 0 |
31 Dec 17 | 57 | -64 | 44 | 0 |
30 Sep 17 | 12 | -96 | 40 | 0 |
30 Jun 17 | 15 | -77 | 37 | 0 |
31 Mar 17 | 18 | -91 | 35 | 0 |
31 Dec 16 | 59 | -48 | 33 | 0 |
30 Sep 16 | 55 | -68 | 31 | 0 |
31 Dec 15 | 292 | 207 | 32 | 0 |
31 Dec 14 | 1 | -77 | 31 | 0 |
Quality Earnings: ATORX is currently unprofitable.
Growing Profit Margin: ATORX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATORX is unprofitable, and losses have increased over the past 5 years at a rate of 5.9% per year.
Accelerating Growth: Unable to compare ATORX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATORX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: ATORX has a negative Return on Equity (-2096.89%), as it is currently unprofitable.